RESIDENCY Flashcards
When to do ABG after hooking to mech vent
Within an hour
Mech vent: How to set TV
6-8cc/kg
Mech vent: How to set FiO2
Begin wih 100, wean as tolerated
Mech vent: How to set PEEP
Begin with 5
ABG parameter to measure oxygenation
PO2
ABG parameter to measure ventilation
PCO2
Parameters to manipulate to alter oxygenation (PO2)
1) FiO2
2) PEEP
3) I-time
Parameters to manipulate to alter ventilation (PCO2)
1) RR
2) TV
3) Shorten I-time to lengthen E-time
Proper ET size
(Age/4) + 4 OR
ET length
Size x 3 OR
Wt. + 6 OR
(Age/2) + 12
Mech vent: How to set rate
Infant: 25-30/min
Child: 15-20/min
Teen: 10-14/min
Incidence of hemophilia A
1/10,000 male births
Incidence of hemophilia B
1/30,000 male births
Symptomatic female carriers of hemophilia A
30%
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
100% in developed countries
% factor activity for adequate hemostasis (hemophilia)
30%
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
Phenobarbital, side effect (WOF when loading)
Respiratory depression
Incidence of hemophilia A
1/10,000 male birthd
Incidence of hemophilia B
1/30,000 male births
Symptomatic female carriers of hemophilia A
30%
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
100% in developed countries
% factor activity for adequate hemostasis (hemophilia)
30%
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
Phenobarbital, side effect (WOF when loading)
Respiratory depression
Incidence of hemophilia A
1/10,000 male birthd
Incidence of hemophilia B
1/30,000 male births
Symptomatic female carriers of hemophilia A
30%
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
100% in developed countries
% factor activity for adequate hemostasis (hemophilia)
30%
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
Phenobarbital, side effect (WOF when loading)
Respiratory depression
